Active Psychotropic Medication Use and Clinical Correlates in Children and Adolescents with Autism Spectrum Disorder
- 1SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ADANA ŞEHİR SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, ÇOCUK PSİKİYATRİSİ ANABİLİM DALI
- 2ÇUKUROVA ÜNİVERSİTESİ
Abstract
Objective: The aim of this study was to describe active psychotropic medication records and agent-level patterns in children and adolescents with autism spectrum disorder (ASD), estimate psychotropic polypharmacy, and identify characteristics associated with an active psychotropic medication record. Method: This single-centre retrospective cross-sectional study included patients with ASD aged 36–216 months who attended a tertiary child and adolescent psychiatry clinic during 2025. Of 172 records assessed, five patients with cognitive impairment attributable to an identified cause other than ASD were excluded; 167 were analysed. Current medications not documented as discontinued were classified as active. Polypharmacy was defined as at least two active psychotropic medications at the same visit. Results: At least one active psychotropic medication was recorded for 123 patients (73.7%; 95% CI 66.5%–79.7%), and polypharmacy for 94 (56.3%; 95% CI 48.7%–63.6%); among the 123 patients with an active record, the polypharmacy proportion was 76.4%. At least one antipsychotic was recorded for 112 patients (67.1%) and at least two for 30 (18.0%). ADHD (aPR = 2.51; 95% CI 1.77–3.55) and irritability (aPR = 1.55; 95% CI 1.28–1.89) were independently associated with an active medication record. Conclusion: Active psychotropic medication records and record-based polypharmacy were frequent in this tertiary-care sample, reflecting electronic health record documentation rather than confirmed medication intake.
Related
- Developmental variation in resting-state EEG spectral correlates of response inhibition in children and adolescents.
- Misophonia in adolescents: clinical correlates and associations with autism-related behavioral characteristics within a clinical context.
- Treatment of growth hormone deficiency with long-acting growth hormones in children, adolescents and adults: Clinical evidence and practical considerations
- Development and contextual adaptation of the first national clinical practice guideline for autism spectrum disorder in children and adolescents in Tunisia
- Clinical characteristics and camouflaging behaviors in children and adolescents with late-diagnosed autism spectrum disorder: a retrospective descriptive study.
BibTeX
@article{varmıs2026active,
title = {{Active Psychotropic Medication Use and Clinical Correlates in Children and Adolescents with Autism Spectrum Disorder}},
author = {Dilek Altun Varmış and Elif Koçak and Cumali Yüksekkaya and Hülya Binokay and Serkan Güneş},
journal = {Psikiyatride Güncel Yaklaşımlar},
year = {2026},
month = oct,
doi = {10.18863/pgy.2017427},
url = {https://doi.org/10.18863/pgy.2017427},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Active Psychotropic Medication Use and Clinical Correlates in Children and Adolescents with Autism Spectrum Disorder
AU - Dilek Altun Varmış
AU - Elif Koçak
AU - Cumali Yüksekkaya
AU - Hülya Binokay
AU - Serkan Güneş
PY - 2026
DA - 2026/10/25
JO - Psikiyatride Güncel Yaklaşımlar
DO - 10.18863/pgy.2017427
UR - https://doi.org/10.18863/pgy.2017427
AB - Objective: The aim of this study was to describe active psychotropic medication records and agent-level patterns in children and adolescents with autism spectrum disorder (ASD), estimate psychotropic polypharmacy, and identify characteristics associated with an active psychotropic medication record. Method: This single-centre retrospective cross-sectional study included patients with ASD aged 36–216 months who attended a tertiary child and adolescent psychiatry clinic during 2025. Of 172 records assessed, five patients with cognitive impairment attributable to an identified cause other than ASD were excluded; 167 were analysed. Current medications not documented as discontinued were classified as active. Polypharmacy was defined as at least two active psychotropic medications at the same visit. Results: At least one active psychotropic medication was recorded for 123 patients (73.7%; 95% CI 66.5%–79.7%), and polypharmacy for 94 (56.3%; 95% CI 48.7%–63.6%); among the 123 patients with an active record, the polypharmacy proportion was 76.4%. At least one antipsychotic was recorded for 112 patients (67.1%) and at least two for 30 (18.0%). ADHD (aPR = 2.51; 95% CI 1.77–3.55) and irritability (aPR = 1.55; 95% CI 1.28–1.89) were independently associated with an active medication record. Conclusion: Active psychotropic medication records and record-based polypharmacy were frequent in this tertiary-care sample, reflecting electronic health record documentation rather than confirmed medication intake.
SN - 1309-0674
SN - 1309-0658
ER -